freeze-thaw comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Domino's Pizza Israel was founded in 1990, and opened their first branch in 1993. They are operated by Elgad Pizza. As of August 2014, there are 33 branches throughout the state. There are four kosher franchises. The rights to own, operate, and franchise branches of the chain in Australia, New Zealand, France, Belgium, the Netherlands, Monaco, Luxembourg, Germany, Japan, Malaysia, Singapore, Taiwan and Cambodia are currently owned by Australian Domino's Pizza Enterprises, having bought the master franchises from the parent company in 1993 (Australian and New Zealand franchises). The Australian company also acquired several European and Asian franchises between 2013 and 2022. It acquired the Danish operations in 2019 but liquidated them in 2023. The master franchises for the UK and Ireland were purchased in 1993 by the British publicly listed Domino's Pizza Group (DPG), which acquired the master franchise for Germany in 2011, and Switzerland, Liechtenstein, and Luxembourg in August 2012 by buying the Swiss master franchise holder, with an option to acquire the Austrian master franchise as well. DPG opened its first Swedish location near the Mobilia shopping mall in Malmö in December 2016; three years later, in 2019, they announced that they would be selling all of their current businesses in the country. In Latin America, the first franchise was opened in 1988 in Colombia. During the next years, Domino's Pizza started operations in Mexico, Guatemala (1989), Chile (1991), Venezuela (1992), Dominican Republic (1993), Ecuador and Peru (1995).
=== Croatia === Croatia finished accession (membership) negotiations on 30 June 2011 and signed the Treaty of Accession on 9 December 2011, setting it on course to become the bloc's 28th member state. A referendum on the EU accession of the Republic of Croatia was held on 22 January 2012. The EU accession referendum passed with 66.27% votes cast in support, 33.13% against the proposed joining of the EU and 0.60% invalid or blank votes; it also passed in all Croatian counties. The ratification process was concluded on 21 June 2013, and entry into force and accession of Croatia to the EU took place on 1 July 2013.
Arabinogalactan-proteins (AGPs) are highly glycosylated proteins (glycoproteins) found in the cell walls of plants. Each one consists of a protein with sugar molecules attached (which can account for more than 90% of the total mass). They are members of the wider class of hydroxyproline (Hyp)-rich cell wall glycoproteins, a large and diverse group of glycosylated wall proteins. AGPs have been reported in a wide range of higher plants in seeds, roots, stems, leaves and inflorescences. AGPs account for only a small portion of the cell wall, usually no more than 1% of dry mass of the primary wall. They have also been reported in secretions of cell culture medium of root, leaf, endosperm and embryo tissues, and some exudate producing cell types such as stylar canal cells are capable of producing lavish amounts of AGPs. They are implicated in various aspects of plant growth and development, including root elongation, somatic embryogenesis, hormone responses, xylem differentiation, pollen tube growth and guidance, programmed cell death, cell expansion, salt tolerance, host-pathogen interactions, and cellular signaling. AGPs have attracted considerable attention due to their highly complex structures and potential roles in signalling. In addition, they have industrial and health applications due to their chemical/physical properties (water-holding, adhesion and emulsification).
Studies suggest that the Af9 protein acts as a repressor of Tbr1 in the upper layers of the six-layer developing cerebral cortex, thereby confining Tbr1 to the lower cortical layers (preplate, subplate, layer VI). This process is regulated through interaction of Af9 with the methyltransferase DOT1L, which methylates histone H3 lysine 79 (H3K79). Af9 association with DOT1L enhances methylation of H3K79 at the TBR1 transcription start site, thereby interfering with RNA polymerase II (RNAPolII) activity and reducing TBR1 expression. Mutants of Af9 experience increased dimethylation of H3K79 and increased TBR1 expression.
== Health concerns == For introduction of radionuclides into an organism, ingestion is the most important route. Insoluble compounds are not absorbed from the gut and cause only local irradiation before they are excreted. Soluble forms however show wide range of absorption percentages.
Sources: en.wikipedia.org
Nevertheless, he continued working in research and became Emeritus Professor of Chemistry and Emeritus Professor of Molecular and Microbial Biosciences. He also voluntarily continued teaching at first-year level. His lecturing was described as "charismatic" and "teaching was a love and a privilege and never an obligation" for him.
Colombia first played Argentina at the 1945 South American Championship in Chile. Argentina holds the superior overall head-to-head record, but the fixture acquired greater prominence during qualification for the 1994 FIFA World Cup. Colombia beat Argentina 2–1 in Barranquilla in August 1993, ending Argentina's 31-match unbeaten run, before winning the return match 5–0 at the Estadio Monumental three weeks later. The result secured Colombia's direct qualification for the 1994 finals, handed Argentina its first home defeat in World Cup qualification, and remains one of the most notable results in Colombian football history. Colombia also defeated Argentina 3–0 in the group stage of the 1999 Copa América, a match in which Martín Palermo missed three penalties. The fixture developed a more openly confrontational dimension during the 2021 Copa América semi-final. After a 1–1 draw, Argentina won the shootout 3–2; goalkeeper Emiliano Martínez repeatedly addressed Colombian takers during the shootout, while Lionel Messi taunted Yerry Mina after Martínez saved Mina's penalty, referring to the defender's goal celebration. Argentina defeated Colombia 1–0 after extra time in the 2024 Copa América final. Their next competitive meeting came in 2026 World Cup qualification in September 2024, when Colombia beat the reigning Copa América champions 2–1 in Barranquilla. The return fixture in Buenos Aires in June 2025 ended 1–1 and included several confrontations between the teams, including a verbal exchange between Lionel Messi and James Rodríguez.
=== Surgical management === In cases involving obstructive cholestasis, the primary treatment includes biliary decompression. If bile stones are present in the common bile duct, an endoscopic sphincterotomy can be conducted either with or without placing a stent. To do this, a duodenoscope is placed by the endoscopist in the second portion of the duodenum. A catheter and guidewire is moved up into the common bile duct. A sphincterotome can then enlarge the ampulla of Vater and release the stones. Later, the endoscopist can place a stent in the common bile duct to soften any remaining stones and allow for bile drainage. If needed, a balloon catheter is available to remove any leftover stones. If these stones are too large with these methods, surgical removal may be needed. Patients can also request an elective cholecystectomy to prevent future cases of choledocholithiasis. In case of narrowing of the common bile duct, a stent can be placed after dilating the constriction to resolve the obstruction. The treatment approach for patients with obstructive cholestasis resulting from cancer varies based on whether they are a suitable candidate for surgery. In most cases, surgical intervention is the best option. For patients whom complete removal of the biliary obstruction is not possible, a combination of a gastric bypass and hepaticojejunostomy can be used. This can reestablish bile flow into the small intestine, thereby bypassing the blockage. In cases where a patient is not a suitable candidate for surgery, an endoscopic stent can be placed.
Moscow has a humid continental climate (Köppen climate classification: Dfb) with long, cold winters usually lasting from mid-November to the end of March, along with warm summers. More extreme continental climates at the same latitude—such as parts of Eastern Canada or Siberia—have much colder winters than Moscow does, suggesting that Moscow receives significant moderation from the Atlantic Ocean, even though the city is distant from it. Weather in Moscow can fluctuate widely: in the winter, temperatures range from −25 °C (−13 °F) in the city and −30 °C (−22 °F) in the suburbs to above 5 °C (41 °F); in the summer, temperatures range from 10 to 35 °C (50 to 95 °F).
Law MY, Halliwell B (1986). "Purification and properties of glutathione synthetase from (Spinacia oleracea) leaves". Plant Sci. 43 (3): 185–191. doi:10.1016/0168-9452(86)90016-6. Macnicol PK (1987). "Homoglutathione and glutathione synthetases of legume seedlings - partial-purification and substrate-specificity". Plant Sci. 53 (3): 229–235. Bibcode:1987PlnSc..53..229M. doi:10.1016/0168-9452(87)90159-2.
Sources: en.wikipedia.org
==== MeSH E05.200.500 – cytological techniques ==== MeSH E05.200.500.105 – autoradiography MeSH E05.200.500.195 – cell count MeSH E05.200.500.195.107 – blood cell count MeSH E05.200.500.195.107.330 – erythrocyte count MeSH E05.200.500.195.107.330.725 – reticulocyte count MeSH E05.200.500.195.107.595 – leukocyte count MeSH E05.200.500.195.107.595.500 – lymphocyte count MeSH E05.200.500.195.107.595.500.150 – cd4 lymphocyte count MeSH E05.200.500.195.107.595.500.150.160 – cd4-cd8 ratio MeSH E05.200.500.195.107.740 – platelet count MeSH E05.200.500.195.870 – sperm count MeSH E05.200.500.251 – cell fractionation MeSH E05.200.500.307 – cell fusion MeSH E05.200.500.363 – cell separation MeSH E05.200.500.363.285 – cytapheresis MeSH E05.200.500.363.285.570 – leukapheresis MeSH E05.200.500.363.285.790 – plateletpheresis MeSH E05.200.500.363.400 – immunomagnetic separation MeSH E05.200.500.363.540 – leukocyte reduction procedures MeSH E05.200.500.383 – colony-forming units assay MeSH E05.200.500.383.910 – tumor stem cell assay MeSH E05.200.500.385 – cytogenetic analysis MeSH E05.200.500.385.130 – chromosome banding MeSH E05.200.500.385.500 – mitotic index MeSH E05.200.500.386 – cytophotometry MeSH E05.200.500.386.350 – flow cytometry MeSH E05.200.500.386.400 – image cytometry MeSH E05.200.500.386.400.500 – laser scanning cytometry MeSH E05.200.500.387 – diffusion chambers, culture MeSH E05.200.500.388 – drug screening assays, antitumor MeSH E05.200.500.388.930 – tumor stem cell assay MeSH E05.200.500.410 – electroporation MeSH E05.200.500.607 – histocytochemistry MeSH E05.200.500.607.512 – immunohistochemistry MeSH E05.200.500.607.790 – periodic acid-schiff reaction MeSH E05.200.500.607.810 – prussian blue reaction MeSH E05.200.500.620 – histocytological preparation techniques MeSH E05.200.500.620.530 – microtomy MeSH E05.200.500.620.530.160 – cryoultramicrotomy MeSH E05.200.500.620.530.160.260 – frozen sections MeSH E05.200.500.620.620 – replica techniques MeSH E05.200.500.620.620.150 – corrosion casting MeSH E05.200.500.620.620.260 – freeze fracturing MeSH E05.200.500.620.620.260.400 – freeze etching MeSH E05.200.500.620.670 – staining and labeling MeSH E05.200.500.620.670.130 – chromosome banding MeSH E05.200.500.620.670.325 – in situ hybridization MeSH E05.200.500.620.670.325.350 – in situ hybridization, fluorescence MeSH E05.200.500.620.670.325.350.125 – chromosome painting MeSH E05.200.500.620.670.325.680 – primed in situ labeling MeSH E05.200.500.620.670.520 – negative staining MeSH E05.200.500.620.670.620 – periodic acid-schiff reaction MeSH E05.200.500.620.670.660 – prussian blue reaction MeSH E05.200.500.620.670.770 – shadowing (histology) MeSH E05.200.500.620.670.780 – silver staining MeSH E05.200.500.620.720 – tissue embedding MeSH E05.200.500.620.720.610 – paraffin embedding MeSH E05.200.500.620.720.640 – plastic embedding MeSH E05.200.500.620.760 – tissue preservation MeSH E05.200.500.620.760.160 – cryopreservation MeSH E05.200.500.620.760.160.260 – freeze drying MeSH E05.200.500.620.760.160.260.270 – freeze substitution MeSH E05.200.500.620.760.720 – tissue fixation MeSH E05.200.500.695 – karyometry MeSH E05.200.500.800 – patch-clamp techniques
In pharmacokinetics, steady state refers to the situation where the overall intake of a drug is fairly in dynamic equilibrium with its elimination. In practice, it is generally considered that once regular dosing of a drug is started, steady state is reached after 3 to 5 times its half-life. In steady state and in linear pharmacokinetics, AUCτ=AUC∞.
== Side effects == The effects of local skin reactions with clascoterone were similar to placebo in two large phase III randomized controlled trials. Suppression of the hypothalamic–pituitary–adrenal axis (HPA axis) may occur during clascoterone therapy in some individuals due to its cortexolone metabolite. HPA axis suppression as measured by the cosyntropin stimulation test was observed to occur in 3 of 42 (7%) of adolescents and adults using clascoterone for acne. HPA axis function returned to normal within 4 weeks following discontinuation of clascoterone. Hyperkalemia (elevated potassium levels) occurred in 5% of clascoterone-treated individuals and 4% of placebo-treated individuals.
== Overdose == There is limited experience with overdose of suvorexant. Suvorexant has been assessed in single doses of as high as 240 mg in clinical studies. The medication dose-dependently produces somnolence. High doses of suvorexant may also cause sleep-onset paralysis in some individuals (2% incidence at doses of 40–240 mg). Treatment of suvorexant overdose is based on symptoms and is supportive. Gastric lavage may be used where appropriate whereas the value of dialysis has not been determined. Because suvorexant has high plasma protein binding, hemodialysis is not expected to enhance elimination of suvorexant.
=== Supercritical fluid chromatography === Supercritical fluid chromatography (SFC) can be used on an analytical scale, where it combines many of the advantages of high-performance liquid chromatography (HPLC) and gas chromatography (GC). It can be used with non-volatile and thermally labile analytes (unlike GC) and can be used with the universal flame ionization detector (unlike HPLC), as well as producing narrower peaks due to rapid diffusion. In practice, the advantages offered by SFC have not been sufficient to displace the widely used HPLC and GC, except in a few cases such as chiral separations and analysis of high-molecular-weight hydrocarbons. For manufacturing, efficient preparative simulated moving bed units are available. The purity of the final products is very high, but the cost makes it suitable only for very high-value materials such as pharmaceuticals.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.